Niagen Bioscience, Inc. NAGE
Set alert
2.40 USD +0.07 +3.00%
At close · Nov 2
2.36 -0.04 -1.49%
After hours · Nov 2, 4:00 PM ET
2.35 Day range 2.41
2.32 52-week range 7.95
- YTD
- -62.26%
- 1 year
- -68.17%
- Open
- 2.36
- Prev close
- 2.33
- Mkt cap
- 191.15M
- Vol
- 557.59K
- Avg vol
- 534.38K
- EPS
- 0.20
- P/E
- 12.00
- Div yield
- 0.00%
More statistics
- Low
- 2.35
- High
- 2.41
- Forward P/E
- 0.00
- Beta
- 2.08
- Short ratio
- 3.35
- Inst. own
- 33.09%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2025
- 50-d avg
- 10.88
- 200-d avg
- 7.00
- 1y target
- 14.90
MAX chart
Events in this range
- May 7, 2025Earnings: 0.04; estimate 0.02; surprise 100%
- Jun 6, 2025Rating: Roth Capital · Buy → Buy
- Aug 6, 2025Earnings: —; estimate 0.02; surprise —%
Signals (82)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Feb 1, 2026 | 9 months ago |
| MACD: Sell Signal | Nov 1, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| RSI: Overbought | May 1, 2025 | 1 year ago |
| RSI: Overbought | Nov 1, 2024 | 2 years ago |
| SMA: Bullish | Mar 1, 2024 | 2 years ago |
| SMA: Bullish | Feb 1, 2024 | 2 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bullish | Jun 1, 2023 | 3 years ago |
| MACD: Buy Signal | May 1, 2023 | 3 years ago |
| SMA: Bearish | Mar 1, 2023 | 3 years ago |
| SMA: Bullish | Jan 1, 2023 | 3 years ago |
| SMA: Bearish | Nov 1, 2021 | 5 years ago |
| MACD: Sell Signal | Oct 1, 2021 | 5 years ago |
| SMA: Bearish | Sep 1, 2021 | 5 years ago |
| RSI: Overbought | Feb 1, 2021 | 5 years ago |
| SMA: Bullish | Oct 1, 2020 | 6 years ago |
| SMA: Bullish | Oct 1, 2020 | 6 years ago |
| SMA: Bearish | Sep 1, 2020 | 6 years ago |
| SMA: Bearish | Sep 1, 2020 | 6 years ago |
Newest 20 of 82.
Analyst view
Consensus: none
Price target (mean) 14.90 +520.8% upside
Now 2.40
- Target (low)
- 9.60
- Target (mean)
- 14.90
- Target (high)
- 23.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00667 | -0.01 – 0.02 | 0.00 | 0.0% | 28.36M | +24.7% | 3 |
| Next quarter | 0.01333 | 0.01 – 0.02 | 0.02 | -33.4% | 30.71M | +20.0% | 3 |
| Current year | 0.10667 | 0.08 – 0.14 | 0.0495 | +115.5% | 123.37M | +23.9% | 3 |
| Next year | 0.20333 | 0.17 – 0.24 | 0.10667 | +90.6% | 148.23M | +20.2% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 10, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 6, 2025 | Roth Capital | Maintained | Buy | Buy |
| May 27, 2025 | Canaccord Genuity | Initiated | — | Buy |
| Apr 8, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 31, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 17, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 10, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 5, 2025 | Ladenburg Thalmann | Maintained | Buy | Buy |
| Nov 6, 2024 | Roth MKM | Maintained | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |